High Performance Antigen Diagnostics
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Health and Human Services (HHS), specifically BARDA through the Rapid Response Partnership Vehicle (RRPV), has issued a Request for Information (RFI) titled "High Performance Antigen Diagnostics." This RFI seeks to understand the landscape of current and next-generation high-performance immunoassay technologies for antigen testing in near-patient settings. Responses are due by 1pm EDT on July 17, 2026.
Purpose & Scope
This RFI aims to identify technologies capable of achieving nucleic acid amplification test (NAAT) levels of clinical performance (approximately 1-10 pg/mL limit of detection or better) and assess their potential for point-of-care, at-home, or remote/field use. The goal is to overcome limitations of conventional antigen tests, such as lower analytical sensitivity and limited multiplexing.
Key areas of interest include:
- High-sensitivity immunoassay platforms for point-of-care, CLIA-waived, or at-home use.
- Next-generation detection technologies enabling ultra-low limits of detection and/or high multiplexing.
- Miniaturization and system integration for portable or fieldable devices.
- Continuous or near-continuous monitoring systems.
- Sample processing and concentration methods to improve low-abundance antigen recovery.
Submission Requirements
Respondents should provide a concise response (PDF or Word, max 5 pages for technical content) addressing:
- Organizational Overview: Description of organization, core expertise, and diagnostics experience.
- Proposed Solution Technical Overview: Detailed description of the high-performance antigen assay/platform, focusing on sensitivity, detection technology, maturity (TRL), workflow, feasibility data (NAAT comparable performance), multiplexing, development timelines, and manufacturing/scalability.
- Infrastructure & Capabilities: Brief description of existing facilities and capabilities.
The technical response should include an Executive Summary (<=0.5 page), Technical Overview (<=4 pages), and Capabilities and Infrastructure (<=0.5 page).
Key Dates & Contact
- Response Due: July 17, 2026, by 1pm EDT
- Published Date: June 17, 2026
- Contact: ATI at rrpv@ati.org
Important Notes
This RFI is for information gathering only and does not constitute a Request for Project Proposal (RPP) or a commitment to issue a solicitation. Submission is voluntary, and BARDA reserves the right to engage further with respondents. All responses will be treated as sensitive information; classified information should not be submitted.